Azithromycin in Chlamydial Urethritis
| Autor: | Michael Verdon, Raymond B. Johnson, Walter E. Stamm, Kimberly A. Workowski |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
medicine.medical_specialty
business.industry General Medicine medicine.disease_cause Azithromycin medicine.disease Gastroenterology Minimum inhibitory concentration Regimen Internal medicine Immunology medicine Sex organ Urethritis Leukocytosis medicine.symptom Chlamydia trachomatis business Pathogen medicine.drug |
| Zdroj: | JAMA: The Journal of the American Medical Association. 270:1934 |
| ISSN: | 0098-7484 |
| DOI: | 10.1001/jama.1993.03510160052025 |
| Popis: | To the Editor. —A single 1-g dose of azithromycin has recently demonstrated effectiveness in treating uncomplicated genital chlamydial infection. 1 As such, azithromycin represents a major advance in the treatment of chlamydial infection and may improve our efforts to limit the spread of this important pathogen. In view of the proven efficacy of the 1-g regimen, we examined whether a lower dose (500 mg) might be as effective in treating chlamydial infection. A lower dose would cost less and might be associated with fewer side effects. Since the mean tissue concentration after a 500-mg dose of azithromycin ranges between 1 and 9 mg/kg, with levels remaining above 1 mg/kg for 2 to 3 days, 2 the expected tissue levels exceed the 90% minimum inhibitory concentration of Chlamydia trachomatis (0.25 mg/L) for at least several days. 3 Eleven men with nongonococcal urethritis, characterized by urethral discharge, microscopic leukocytosis, and positive rapid |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|